An observational study in Anterior Uveitis (AU), Birdshot Chorioretinitis and Behcet Disease, sponsored by Oregon Health and Science University. Recruiting at 1 site in United States. Open to participants aged 5 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-17.
Sponsored by Oregon Health and Science University · Observational
The goal of this study is to determine if it's possible to use a high resolution imaging device called optical coherence tomography (OCT) to develop an unbiased, standard method of counting and categorizing the various types of cells and proteins found in an eye condition called anterior uveitis. Anterior uveitis is a type of inflammation in the eye that can be caused by many different diseases of the body.
136 studies on the registry are indexed under Behcet Syndrome; 42 are open to participants now.
This study's planned enrollment of 125 is above the median of 90 across 63 observational studies indexed under Behcet Syndrome.
Browse Behcet Syndrome studies →Oregon Health and Science University is the lead sponsor of 696 studies on the registry; 131 are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 39 (75%) have results posted.
Compared within Behcet Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Uveitis, Anterior. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Study participants will be recruited from clinical practices of the investigators at Casey Eye Institute of Oregon Health \& Science University in Portland, Oregon.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eyes with active inflammation due to various systemic diseases
Eyes with vitreous floaters and posterior vitreous detachment
Healthy eyes with no history of uveitis, posterior vitreous detachment, or previous eye surgery
Identification & Measurement of Anterior Chamber Cells
Anterior Chamber (AC) cells will be identified from OCT images by computer algorithms. AC cell number counted by OCT will be correlated with slit lamp grading. Cell size \& other characteristics identified from OCT images will be associated with different uveitis diagnostic categories. The Standardization of Uveitis Nomenclature (SUN) grading system (scale: 0 = none to 4+ = severe) will be used to compare OCT-derived quantification against slit-lamp grading performed by attending physicians.
Time frame: Day 1
Measure of AC Flare
OCT signal of the aqueous humor will be analyzed and correlated with slit lamp grading by the attending physician. The SUN grading system (scale: 0 to 4+) will be used.
Time frame: Day 1
Measure of Keratic Precipitates
Keratic precipitates (KPs) will be identified from OCT images. The size of the KPs will be compared across different uveitis diagnostic categories. There is no formal grading system for KPs. The investigators will use the typical qualitative assessments of morphology, distribution, and density. For morphology, cells will be described as fine, mutton-fat, stellate, or pigmented. Distribution patterns will be described as Arlt's Triangle, diffuse, central, or ring-shaped. Density will be described as few, moderate, or numerous.
Time frame: Day 1
Measure of Vitreous Cells
Vitreous cells will be identified from OCT images. Counting of vitreous cells will be done by computer algorithms. Since vitreous cells are not formally graded or quantified in the SUN system, physician grading will be described as rare, few, moderate, numerous, or sheets and compared against the OCT-derived measurements.
Time frame: Day 1
Measurement of Vitreous Haze
OCT signal of the vitreous clarity will be compared against clinical grading of vitreous haze. The National Eye Institute (NEI) Grading Scale will be used. Grading will be documented on a scale of 0 = no haze to 4+ = severe haze.
Time frame: Day 1
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Sep 2026, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oregon Health and Science University →